Literature DB >> 24074193

A systematic review comparing cognitive-behavioral therapy and contingency management for cocaine dependence.

Nadine S Farronato1, Kenneth M Dürsteler-Macfarland, Gerhard A Wiesbeck, Sylvie A Petitjean.   

Abstract

The main objective of this review was to compare the effectiveness of cognitive-behavioral therapy and contingency management for cocaine dependence. Contingency management alone reliably reduced cocaine use during active treatment in all cited trials, whereas the positive effect of cognitive-behavioral therapy emerged after treatment in 3 of 5 trials. Synergistic effects of the combination of contingency management plus cognitive-behavioral therapy are shown in 2 trials, but another 3 trials found no additive effects. Positive, rapid, and enduring effects on cocaine use are reliably seen with contingency management interventions, whereas measurable effects of cognitive-behavioral therapy emerge after treatment and are not as reliable as effects with contingency management.

Entities:  

Mesh:

Year:  2013        PMID: 24074193     DOI: 10.1080/10550887.2013.824328

Source DB:  PubMed          Journal:  J Addict Dis        ISSN: 1055-0887


  12 in total

1.  Pharmacotherapeutic strategies for treating cocaine use disorder-what do we have to offer?

Authors:  Laura Brandt; Thomas Chao; Sandra D Comer; Frances R Levin
Journal:  Addiction       Date:  2020-09-28       Impact factor: 6.526

2.  Methadone maintenance therapy and viral suppression among HIV-infected opioid users: The impacts of crack and injection cocaine use.

Authors:  M Eugenia Socías; Evan Wood; Will Small; Huiru Dong; Jean Shoveller; Thomas Kerr; Julio Montaner; M-J Milloy
Journal:  Drug Alcohol Depend       Date:  2016-09-20       Impact factor: 4.492

3.  Anhedonia Is Associated with Poorer Outcomes in Contingency Management for Cocaine Use Disorder.

Authors:  Margaret C Wardle; Jessica N Vincent; Robert Suchting; Charles E Green; Scott D Lane; Joy M Schmitz
Journal:  J Subst Abuse Treat       Date:  2016-09-09

4.  How can we investigate the role of topiramate in the treatment of cocaine use disorder more thoroughly?

Authors:  Jan Klimas; Evan Wood; Daniel Werb
Journal:  Addiction       Date:  2016-11-03       Impact factor: 6.526

5.  Risk factors for stimulant use among homeless and unstably housed adult women.

Authors:  Elise D Riley; Martha Shumway; Kelly R Knight; David Guzman; Jennifer Cohen; Sheri D Weiser
Journal:  Drug Alcohol Depend       Date:  2015-05-27       Impact factor: 4.492

6.  Initial abstinence status and contingency management treatment outcomes: does race matter?

Authors:  LaTrice Montgomery; Kathleen M Carroll; Nancy M Petry
Journal:  J Consult Clin Psychol       Date:  2015-03-23

7.  Testing the differential effects of symptom management interventions in cancer.

Authors:  Alla Sikorskii; Charles W Given; Azfar-E-Alam Siddiqi; Victoria Champion; Ruth McCorkle; Sandra L Spoelstra; Barbara A Given
Journal:  Psychooncology       Date:  2014-04-15       Impact factor: 3.894

8.  Long-term efficacy of contingency management treatment based on objective indicators of abstinence from illicit substance use up to 1 year following treatment: A meta-analysis.

Authors:  Meredith K Ginley; Rory A Pfund; Carla J Rash; Kristyn Zajac
Journal:  J Consult Clin Psychol       Date:  2021-01

9.  Treatment of stimulant use disorder: A systematic review of reviews.

Authors:  Claire Ronsley; Seonaid Nolan; Rod Knight; Kanna Hayashi; Jano Klimas; Alex Walley; Evan Wood; Nadia Fairbairn
Journal:  PLoS One       Date:  2020-06-18       Impact factor: 3.240

10.  Comparative efficacy and acceptability of psychosocial interventions for individuals with cocaine and amphetamine addiction: A systematic review and network meta-analysis.

Authors:  Franco De Crescenzo; Marco Ciabattini; Gian Loreto D'Alò; Riccardo De Giorgi; Cinzia Del Giovane; Carolina Cassar; Luigi Janiri; Nicolas Clark; Michael Joshua Ostacher; Andrea Cipriani
Journal:  PLoS Med       Date:  2018-12-26       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.